Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages.
Biomarker
Glycosylation
Macrophage
Oncofetal fibronectin
Polarization
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
27
06
2022
accepted:
11
09
2022
pubmed:
6
10
2022
medline:
20
1
2023
entrez:
5
10
2022
Statut:
ppublish
Résumé
Macrophage (Mϕ) polarization is an essential phenomenon for the maintenance of homeostasis and tissue repair, and represents the event by which Mϕ reach divergent functional phenotypes as a result to specific stimuli and/or microenvironmental signals. Mϕ can be polarized into two main phenotypes, M1 or classically activated and M2 or alternatively activated. These two categories diverge in many aspects, such as secreted cytokines, markers of cell surface, and biological functions. Over the last 10 years, many potential markers have been proposed for both M1 and M2 human Mϕ. However, there is scarce information regarding the glycophenotype adopted by these cells. Here, we show that M2- but not M1-polarized Mϕ expresses high levels of an unusual glycoform of fibronectin (FN), named O-glycosylated oncofetal FN (onf-FN), found in fetal/cancer cells, but not in healthy tissues. The onf-FN expression was confirmed in vitro by Western blot and real-time RT-qPCR in primary and cell line monocyte-derived Mϕ. onf-FN was induced by IL-4 and IL-13, but not by pro-inflammatory stimuli (LPS and INF-γ). RNA and protein analysis clearly demonstrated that it is specifically associated with the M2 polarization. In conclusion, we show by the first time that O-glycosylated onf-FN is expressed by M2-polarized Mϕ.
Identifiants
pubmed: 36197587
doi: 10.1007/s12026-022-09321-9
pii: 10.1007/s12026-022-09321-9
doi:
Substances chimiques
oncofetal fibronectin
0
Fibronectins
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-104Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. https://doi.org/10.1016/j.immuni.2014.06.008 .
doi: 10.1016/j.immuni.2014.06.008
Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61. https://doi.org/10.2741/2692 .
doi: 10.2741/2692
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55. https://doi.org/10.1016/s1471-4906(02)02302-5 .
doi: 10.1016/s1471-4906(02)02302-5
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95. https://doi.org/10.1172/JCI59643 .
doi: 10.1172/JCI59643
Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47. https://doi.org/10.1146/annurev-pathmechdis-012418-012718 .
doi: 10.1146/annurev-pathmechdis-012418-012718
Xiao M, Zhang J, Chen W, Chen W. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2018;37(1):143. https://doi.org/10.1186/s13046-018-0815-2 .
doi: 10.1186/s13046-018-0815-2
Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, et al. Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Res. 2018;78(15):4253–69. https://doi.org/10.1158/0008-5472.CAN-17-3876 .
doi: 10.1158/0008-5472.CAN-17-3876
Kolliniati O, Ieronymaki E, Vergadi E, Tsatsanis C. Metabolic regulation of macrophage activation. J Innate Immun. 2022;14(1):51–68. https://doi.org/10.1159/000516780 .
doi: 10.1159/000516780
Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112. https://doi.org/10.1186/1471-2407-10-112 .
doi: 10.1186/1471-2407-10-112
Mills CD. M1 and M2 Macrophages: oracles of health and disease. Crit Rev Immunol. 2012;32(6):463–88. https://doi.org/10.1615/critrevimmunol.v32.i6.10 .
doi: 10.1615/critrevimmunol.v32.i6.10
Pan XQ. The mechanism of the anticancer function of M1 macrophages and their use in the clinic. Chin J Cancer. 2012;31(12):557–63. https://doi.org/10.5732/cjc.012.10046 .
doi: 10.5732/cjc.012.10046
Nascimento CS, Alves EAR, de Melo CP, Correa-Oliveira R, Calzavara-Silva CE. Immunotherapy for cancer: effects of iron oxide nanoparticles on polarization of tumor-associated macrophages. Nanomedicine (Lond). 2021;16(29):2633–50. https://doi.org/10.2217/nnm-2021-0255 .
doi: 10.2217/nnm-2021-0255
Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35. https://doi.org/10.1038/nri978 .
doi: 10.1038/nri978
Dungan LS, McGuinness NC, Boon L, Lynch MA, Mills KH. Innate IFN-gamma promotes development of experimental autoimmune encephalomyelitis: a role for NK cells and M1 macrophages. Eur J Immunol. 2014;44(10):2903–17. https://doi.org/10.1002/eji.201444612 .
doi: 10.1002/eji.201444612
Eom YW, Akter R, Li W, Lee S, Hwang S, Kim J et al. M1 macrophages promote TRAIL expression in adipose tissue-derived stem cells, which suppresses colitis-associated colon cancer by increasing apoptosis of CD133(+) cancer stem cells and decreasing M2 macrophage population. Int J Mol Sci. 2020;21(11):1–15. https://doi.org/10.3390/ijms21113887 .
Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 Macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1beta signaling. Front Immunol. 2019;10:1643. https://doi.org/10.3389/fimmu.2019.01643 .
doi: 10.3389/fimmu.2019.01643
Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B, et al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle. 2018;17(4):428–38. https://doi.org/10.1080/15384101.2018.1444305 .
doi: 10.1080/15384101.2018.1444305
Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176–85. https://doi.org/10.1002/path.4133 .
doi: 10.1002/path.4133
Yan W, Li T, Yin T, Hou Z, Qu K, Wang N, et al. M2 macrophage-derived exosomes promote the c-KIT phenotype of vascular smooth muscle cells during vascular tissue repair after intravascular stent implantation. Theranostics. 2020;10(23):10712–28. https://doi.org/10.7150/thno.46143 .
doi: 10.7150/thno.46143
Bardi GT, Smith MA, Hood JL. Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine. 2018;105:63–72. https://doi.org/10.1016/j.cyto.2018.02.002 .
doi: 10.1016/j.cyto.2018.02.002
Yu T, Zhao L, Huang X, Ma C, Wang Y, Zhang J, et al. Enhanced activity of the macrophage M1/M2 phenotypes and phenotypic switch to M1 in periodontal infection. J Periodontol. 2016;87(9):1092–102. https://doi.org/10.1902/jop.2016.160081 .
doi: 10.1902/jop.2016.160081
Vega-Galaviz D, Vecchyo-Tenorio GD, Alcantara-Suarez R, Mendez-Garcia LA, Sanchez-Del Real AL, Villalobos-Molina R, et al. M2 macrophage immunotherapy abolishes glucose intolerance by increasing IL-10 expression and AKT activation. Immunotherapy. 2020;12(1):9–24. https://doi.org/10.2217/imt-2019-0080 .
doi: 10.2217/imt-2019-0080
Vogel DY, Glim JE, Stavenuiter AW, Breur M, Heijnen P, Amor S, et al. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology. 2014;219(9):695–703. https://doi.org/10.1016/j.imbio.2014.05.002 .
doi: 10.1016/j.imbio.2014.05.002
Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE. 2010;5(1): e8668. https://doi.org/10.1371/journal.pone.0008668 .
doi: 10.1371/journal.pone.0008668
Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):1–21. https://doi.org/10.3390/ijms22136995 .
Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437–46. https://doi.org/10.1158/0008-5472.CAN-04-4262 .
doi: 10.1158/0008-5472.CAN-04-4262
Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006;66(23):11432–40. https://doi.org/10.1158/0008-5472.CAN-06-1867 .
doi: 10.1158/0008-5472.CAN-06-1867
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96. https://doi.org/10.1038/ni.1937 .
doi: 10.1038/ni.1937
Biswas SK, Lewis CE. NF-kappaB as a central regulator of macrophage function in tumors. J Leukoc Biol. 2010;88(5):877–84. https://doi.org/10.1189/jlb.0310153 .
doi: 10.1189/jlb.0310153
Dorrington MG, Fraser IDC. NF-kappaB signaling in macrophages: dynamics, crosstalk, and signal integration. Front Immunol. 2019;10:705. https://doi.org/10.3389/fimmu.2019.00705 .
doi: 10.3389/fimmu.2019.00705
Ernst O, Vayttaden SJ, Fraser IDC. Measurement of NF-kappaB activation in TLR-activated macrophages. Methods Mol Biol. 2018;1714:67–78. https://doi.org/10.1007/978-1-4939-7519-8_5 .
doi: 10.1007/978-1-4939-7519-8_5
Quero L, Tiaden AN, Hanser E, Roux J, Laski A, Hall J, et al. miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation. Front Immunol. 2019;10:3087. https://doi.org/10.3389/fimmu.2019.03087 .
doi: 10.3389/fimmu.2019.03087
Xu H, An H, Yu Y, Zhang M, Qi R, Cao X. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. J Biol Chem. 2003;278(38):36334–40. https://doi.org/10.1074/jbc.M305698200 .
doi: 10.1074/jbc.M305698200
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128(2):805–15. https://doi.org/10.1172/JCI96113 .
doi: 10.1172/JCI96113
Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543(7645):428–32. https://doi.org/10.1038/nature21409 .
doi: 10.1038/nature21409
Yang X, Feng W, Wang R, Yang F, Wang L, Chen S, et al. Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology. 2018;7(4):e1412910. https://doi.org/10.1080/2162402X.2017.1412910 .
doi: 10.1080/2162402X.2017.1412910
Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161–7. https://doi.org/10.1038/sj.onc.1210911 .
doi: 10.1038/sj.onc.1210911
Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol. 2010;12(4):401–8. https://doi.org/10.1093/neuonc/nop047 .
doi: 10.1093/neuonc/nop047
Weber JS, Zarour H, Redman B, Trefzer U, O’Day S, van den Eertwegh AJ, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009;115(17):3944–54. https://doi.org/10.1002/cncr.24473 .
doi: 10.1002/cncr.24473
Bleriot C, Chakarov S, Ginhoux F. Determinants of resident tissue macrophage identity and function. Immunity. 2020;52(6):957–70. https://doi.org/10.1016/j.immuni.2020.05.014 .
doi: 10.1016/j.immuni.2020.05.014
Davies LC, Taylor PR. Tissue-resident macrophages: then and now. Immunology. 2015;144(4):541–8. https://doi.org/10.1111/imm.12451 .
doi: 10.1111/imm.12451
O’Shannessy DJ, Somers EB, Wang LC, Wang H, Hsu R. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J Ovarian Res. 2015;8:29. https://doi.org/10.1186/s13048-015-0156-0 .
doi: 10.1186/s13048-015-0156-0
Tariq M, Zhang JQ, Liang GK, He QJ, Ding L, Yang B. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017;38(11):1501–11. https://doi.org/10.1038/aps.2017.124 .
doi: 10.1038/aps.2017.124
Zhang X, Zhao Y, Zhu X, Guo Y, Yang Y, Jiang Y, et al. Active vitamin D regulates macrophage M1/M2 phenotypes via the STAT-1-TREM-1 pathway in diabetic nephropathy. J Cell Physiol. 2019;234(5):6917–26. https://doi.org/10.1002/jcp.27450 .
doi: 10.1002/jcp.27450
Wu BM, Liu JD, Li YH, Li J. Margatoxin mitigates CCl4induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling. Int J Mol Med. 2020;45(1):103–14. https://doi.org/10.3892/ijmm.2019.4395 .
doi: 10.3892/ijmm.2019.4395
Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176(1):287–92. https://doi.org/10.1084/jem.176.1.287 .
doi: 10.1084/jem.176.1.287
Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004;304(5677):1678–82. https://doi.org/10.1126/science.1095336 .
doi: 10.1126/science.1095336
Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, Hassanzadeh GhG. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol. 2002;71(4):597–602.
doi: 10.1189/jlb.71.4.597
Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303–11. https://doi.org/10.4049/jimmunol.177.10.7303 .
doi: 10.4049/jimmunol.177.10.7303
Gerrick KY, Gerrick ER, Gupta A, Wheelan SJ, Yegnasubramanian S, Jaffee EM. Transcriptional profiling identifies novel regulators of macrophage polarization. PLoS ONE. 2018;13(12):e0208602. https://doi.org/10.1371/journal.pone.0208602 .
doi: 10.1371/journal.pone.0208602
Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577. https://doi.org/10.1186/s12885-015-1546-9 .
doi: 10.1186/s12885-015-1546-9
Sudhakaran PR, Radhika A, Jacob SS. Monocyte macrophage differentiation in vitro: fibronectin-dependent upregulation of certain macrophage-specific activities. Glycoconj J. 2007;24(1):49–55. https://doi.org/10.1007/s10719-006-9011-2 .
doi: 10.1007/s10719-006-9011-2
Jacob SS, Shastry P, Sudhakaran PR. Monocyte-macrophage differentiation in vitro: modulation by extracellular matrix protein substratum. Mol Cell Biochem. 2002;233(1–2):9–17. https://doi.org/10.1023/a:1015593232347 .
doi: 10.1023/a:1015593232347
Digiacomo G, Tusa I, Bacci M, Cipolleschi MG, Dello Sbarba P, Rovida E. Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway. Cell Adh Migr. 2017;11(4):327–37. https://doi.org/10.1080/19336918.2016.1221566 .
doi: 10.1080/19336918.2016.1221566
Pietrocola G, Rindi S, Nobile G, Speziale P. Purification of human plasma/cellular fibronectin and fibronectin fragments. Methods Mol Biol. 2017;1627:309–24. https://doi.org/10.1007/978-1-4939-7113-8_20 .
doi: 10.1007/978-1-4939-7113-8_20
Mosher DF. Cross-linking of plasma and cellular fibronectin by plasma transglutaminase. Ann N Y Acad Sci. 1978;312:38–42. https://doi.org/10.1111/j.1749-6632.1978.tb16791.x .
doi: 10.1111/j.1749-6632.1978.tb16791.x
Krusius T, Fukuda M, Dell A, Ruoslahti E. Structure of the carbohydrate units of human amniotic fluid fibronectin. J Biol Chem. 1985;260(7):4110–6.
doi: 10.1016/S0021-9258(18)89238-9
Sekiguchi K, Hakomori S. Functional domain structure of fibronectin. Proc Natl Acad Sci U S A. 1980;77(5):2661–5. https://doi.org/10.1073/pnas.77.5.2661 .
doi: 10.1073/pnas.77.5.2661
Schor SL, Grey AM, Ellis I, Schor AM, Coles B, Murphy R. Migration stimulating factor (MSF): its structure, mode of action and possible function in health and disease. Symp Soc Exp Biol. 1993;47:235–51.
Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J, et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res. 2003;63(24):8827–36.
Schor AM, Woolston AM, Kankova K, Harada K, Aljorani LE, Perrier S, et al. Migration stimulating factor (MSF): its role in the tumour microenvironment. Adv Exp Med Biol. 2021;1329:351–97. https://doi.org/10.1007/978-3-030-73119-9_18 .
doi: 10.1007/978-3-030-73119-9_18
Schor AM, Schor SL. Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention. Eye (Lond). 2010;24(3):450–8. https://doi.org/10.1038/eye.2009.314 .
doi: 10.1038/eye.2009.314
Schor SL, Grey AM, Picardo M, Schor AM, Howell A, Ellis I, et al. Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): implications for cancer pathogenesis. EXS. 1991;59:127–46. https://doi.org/10.1007/978-3-0348-7494-6_9 .
doi: 10.1007/978-3-0348-7494-6_9
da Fonseca LM, da Silva VA, Freire-de-Lima L, Previato JO, Mendonca-Previato L, Capella MA. Glycosylation in cancer: interplay between multidrug resistance and epithelial-to-mesenchymal transition? Front Oncol. 2016;6:158. https://doi.org/10.3389/fonc.2016.00158 .
doi: 10.3389/fonc.2016.00158
Freire-de-Lima L. Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Front Oncol. 2014;4:59. https://doi.org/10.3389/fonc.2014.00059 .
doi: 10.3389/fonc.2014.00059
da Fonseca LM, Calvalhan DM, Previato JO, Mendonca Previato L, Freire-de-Lima L. Resistance to paclitaxel induces glycophenotype changes and mesenchymal-to-epithelial transition activation in the human prostate cancer cell line PC-3. Tumour Biol. 2020;42(9):1010428320957506. https://doi.org/10.1177/1010428320957506 .
doi: 10.1177/1010428320957506
Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K, et al. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc Natl Acad Sci U S A. 2011;108(43):17690–5. https://doi.org/10.1073/pnas.1115191108 .
doi: 10.1073/pnas.1115191108
da Fonseca LM, da Silva VA, da Costa KM, Dos Reis JS, Previato JO, Previato LM, et al. Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers. Glycoconj J. 2022. https://doi.org/10.1007/s10719-022-10042-2 .
doi: 10.1007/s10719-022-10042-2
Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem. 1988;263(7):3314–22.
doi: 10.1016/S0021-9258(18)69074-X
Vendittelli F, Raffaelli M, Fadda G, Carelli-Alinovi C, Paolillo C, Bellantone R, et al. Blood presence of circulating oncofetal fibronectin mRNA, by RT-PCR, does not represent a useful specific marker for the management and follow-up of thyroid cancer patients. Clin Chem Lab Med. 2012;50(4):715–20. https://doi.org/10.1515/cclm-2011-0848 .
doi: 10.1515/cclm-2011-0848
Feinberg RF, Kliman HJ, Wang CL. Transforming growth factor-beta stimulates trophoblast oncofetal fibronectin synthesis in vitro: implications for trophoblast implantation in vivo. J Clin Endocrinol Metab. 1994;78(5):1241–8. https://doi.org/10.1210/jcem.78.5.8175984 .
doi: 10.1210/jcem.78.5.8175984
Menzin AW, Loret de Mola JR, Bilker WB, Wheeler JE, Rubin SC, Feinberg RF. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. Cancer. 1998;82(1):152–8. https://doi.org/10.1002/(sici)1097-0142(19980101)82:1%3c152::aid-cncr19%3e3.0.co;2-1 .
doi: 10.1002/(sici)1097-0142(19980101)82:1<152::aid-cncr19>3.0.co;2-1
Jaatinen T, Laine J. Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient. Curr Protoc Stem Cell Biol. 2007;Chapter 2:Unit 2A 1. https://doi.org/10.1002/9780470151808.sc02a01s1 .
Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23(1):37–45. https://doi.org/10.1016/j.intimp.2014.08.002 .
doi: 10.1016/j.intimp.2014.08.002
Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129(4):1016–25. https://doi.org/10.1038/jid.2008.310 .
doi: 10.1038/jid.2008.310
Freire-de-Lima L, Nardy A, Ramos-Junior ES, Conde L, Santos Lemos J, da Fonseca LM, et al. Multiple myeloma cells express key immunoregulatory cytokines and modulate the monocyte migratory response. Front Med (Lausanne). 2017;4:92. https://doi.org/10.3389/fmed.2017.00092 .
doi: 10.3389/fmed.2017.00092
Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci U S A. 1985;82(19):6517–21. https://doi.org/10.1073/pnas.82.19.6517 .
doi: 10.1073/pnas.82.19.6517
Ding Y, Gelfenbeyn K, Freire-de-Lima L, Handa K, Hakomori SI. Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin. FEBS Lett. 2012;586(13):1813–20. https://doi.org/10.1016/j.febslet.2012.05.020 .
doi: 10.1016/j.febslet.2012.05.020
Silva-Aguiar RP, Peruchetti DB, Florentino LS, Takiya CM, Marzolo MP, Dias WB et al. Albumin expands albumin reabsorption capacity in proximal tubule epithelial cells through a positive feedback loop between AKT and megalin. Int J Mol Sci. 2022;23(2):1–17. https://doi.org/10.3390/ijms23020848 .
Lomovskaya YV, Kobyakova MI, Senotov AS, Lomovsky AI, Minaychev VV, Fadeeva IS et al. Macrophage-like THP-1 cells derived from high-density cell culture are resistant to TRAIL-induced cell death via down-regulation of death-receptors DR4 and DR5. Biomolecules. 2022;12(2):1–19. https://doi.org/10.3390/biom12020150 .
Alisson-Silva F, Freire-de-Lima L, Donadio JL, Lucena MC, Penha L, Sa-Diniz JN, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS ONE. 2013;8(4): e60471. https://doi.org/10.1371/journal.pone.0060471 .
doi: 10.1371/journal.pone.0060471
Maess MB, Wittig B, Cignarella A, Lorkowski S. Reduced PMA enhances the responsiveness of transfected THP-1 macrophages to polarizing stimuli. J Immunol Methods. 2014;402(1–2):76–81. https://doi.org/10.1016/j.jim.2013.11.006 .
doi: 10.1016/j.jim.2013.11.006
Liguori M, Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel). 2011;3(4):3740–61. https://doi.org/10.3390/cancers3043740 .
doi: 10.3390/cancers3043740
Matsuura H, Greene T, Hakomori S. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J Biol Chem. 1989;264(18):10472–6.
doi: 10.1016/S0021-9258(18)81645-3
Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos CE, Schledzewski K, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol. 2001;53(4):386–92. https://doi.org/10.1046/j.1365-3083.2001.00885.x .
doi: 10.1046/j.1365-3083.2001.00885.x
Gudewicz PW, Molnar J, Lai MZ, Beezhold DW, Siefring GE Jr, Credo RB, et al. Fibronectin-mediated uptake of gelatin-coated latex particles by peritoneal macrophages. J Cell Biol. 1980;87(2 Pt 1):427–33. https://doi.org/10.1083/jcb.87.2.427 .
doi: 10.1083/jcb.87.2.427
Falcone DJ, Salisbury BG. Fibronectin stimulates macrophage uptake of low density lipoprotein-heparin-collagen complexes. Arteriosclerosis. 1988;8(3):263–73. https://doi.org/10.1161/01.atv.8.3.263 .
doi: 10.1161/01.atv.8.3.263
Sikkema AH, Stoffels JMJ, Wang P, Basedow FJ, Bulsink R, Bajramovic JJ, et al. Fibronectin aggregates promote features of a classically and alternatively activated phenotype in macrophages. J Neuroinflammation. 2018;15(1):218. https://doi.org/10.1186/s12974-018-1238-x .
doi: 10.1186/s12974-018-1238-x
Li Z, Bratlie KM. Macrophage phenotypic changes on FN-coated physical gradient hydrogels. ACS Appl Bio Mater. 2021;4(9):6758–68. https://doi.org/10.1021/acsabm.1c00489 .
doi: 10.1021/acsabm.1c00489
Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115(Pt 20):3861–3. https://doi.org/10.1242/jcs.00059 .
doi: 10.1242/jcs.00059
Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol. 2010;185(1):642–52. https://doi.org/10.4049/jimmunol.1000413 .
doi: 10.4049/jimmunol.1000413
Baum LG, Crocker PR. Glycoimmunology: ignore at your peril! Immunol Rev. 2009;230(1):5–8. https://doi.org/10.1111/j.1600-065X.2009.00800.x .
doi: 10.1111/j.1600-065X.2009.00800.x
van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008;9(6):593–601. https://doi.org/10.1038/ni.f.203 .
doi: 10.1038/ni.f.203
Macauley MS, Rademacher C, Marino KV. Editorial: Addressing roles for glycans in immunology using chemical biology. Front Chem. 2020;8:471. https://doi.org/10.3389/fchem.2020.00471 .
doi: 10.3389/fchem.2020.00471
Mantuano NR, Oliveira-Nunes MC, Alisson-Silva F, Dias WB, Todeschini AR. Emerging role of glycosylation in the polarization of tumor-associated macrophages. Pharmacol Res. 2019;146: 104285. https://doi.org/10.1016/j.phrs.2019.104285 .
doi: 10.1016/j.phrs.2019.104285
Delannoy CP, Rombouts Y, Groux-Degroote S, Holst S, Coddeville B, Harduin-Lepers A, et al. Glycosylation changes triggered by the differentiation of monocytic THP-1 cell line into macrophages. J Proteome Res. 2017;16(1):156–69. https://doi.org/10.1021/acs.jproteome.6b00161 .
doi: 10.1021/acs.jproteome.6b00161
Hinneburg H, Pedersen JL, Bokil NJ, Pralow A, Schirmeister F, Kawahara R, et al. High-resolution longitudinal N- and O-glycoprofiling of human monocyte-to-macrophage transition. Glycobiology. 2020;30(9):679–94. https://doi.org/10.1093/glycob/cwaa020 .
doi: 10.1093/glycob/cwaa020
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–82. https://doi.org/10.1038/s41577-019-0127-6 .
doi: 10.1038/s41577-019-0127-6
Liu J, Geng X, Hou J, Wu G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21(1):389. https://doi.org/10.1186/s12935-021-02089-2 .
doi: 10.1186/s12935-021-02089-2